Effect of Qidi Xiaoke Capsule Combined with Dapagliflozin on Renal Function and Pyroptosis Factors Levels in Patients with Diabetic Nephropathy

doi:10.3870/j.issn.1672-8009.2026.02.006

Abstract

Abstract: Objective To evaluate the effect of Qidi Xiaoke capsule combined with dapagliflozin on renal function and pyroptosis factors levels in patients with diabetic nephropathy(DN). Methods A total of 121 DN patients were divided into study group(n=60)and control group(n=61). The control group was given dapagliflozin, and study group received Qidi Xiaoke capsule combined with dapagliflozin. The traditional Chinese medicine(TCM)syndrome score, fasting blood glucose(FPG), 2-h postprandial blood glucose(2hPG), glycated hemoglobin(HbA1c), urea nitrogen(BUN), blood creatinine(Scr), 24-h urinary protein(24 h UP), NOD-like receptor thermal protein domain associated protein 3(NLRP3), cysteine aspartate-specific proteinase-1(Caspase-1), interleukin-18(IL-18), interleukin-1β(IL-1β), clinical efficacy and adverse reactions were compared between the two groups. Results After treatment, the TCM syndrome score of study group was lower than that of control group(P<0. 05). The HbA1c, 2hPG and FBG of study group were lower than those of control group(P<0. 05). The eGFR of study group was higher than that of control group, BUN, Scr and 24 h UP were lower than in the control group(P<0. 05). The NLRP3, Caspase-1, IL-18 and IL-1β of study group were lower than control group(P<0. 05). The clinical efficacy of study group was better than that of control group(P<0. 05). There was no significance in adverse reactions between the two groups(P＞0. 05). Conclusion Qidi Xiaoke capsule combined with Dapagliflozin in the treatment of DN is safe and effective, and can improve clinical symptoms, blood glucose level and renal function, the mechanism may be related to regulation of pyroptosis factors.

Key words: Qidi Xiaoke capsule, diabetic nephropathy, pyroptosis, NOD-like receptor thermal protein domain associated protein 3, dapagliflozin

CLC Number:

R587.2

GAO Fang, LI Hong, ZHU Jian, QI Wenshuai, LIU Suwen. Effect of Qidi Xiaoke Capsule Combined with Dapagliflozin on Renal Function and Pyroptosis Factors Levels in Patients with Diabetic Nephropathy[J]. Journal of Medical Molecular Biology, 2026, 23(2): 150-155.

References

[1] YU S,LI Y,LU X,et al.The regulatory role of miRNA and lncRNA on autophagy in diabetic nephropathy[J].Cell Signal,2024,118:111144.
[2] 中华医学会内分泌学分会,中国内分泌代谢病专科联盟.中国糖尿病合并慢性肾脏病临床管理共识[J].中华内分泌代谢杂志,2024,40(6):455-461.
The Endocrine Society of the Chinese Medical Association,Chinese Endocrine and Metabolic Diseases Specialist Alliance.Clinical management consensus on diabetes mellitus and chronic kidney disease in China[J].Chin J Endocrinol Metab,2024,40(6):455-461.
[3] 中华医学会糖尿病学分会.中国糖尿病防治指南(2024版)[J].中华糖尿病杂志,2025,17(1):16-139.
Chinese Medical Association Diabetes Section.Guidelines for the Prevention and Treatment of Diabetes in China(2024 Edition)[J].Chin J Diabetes Mellitus,2025,17(1):16-139.
[4] 庞健丽,钟润芬.左归丸加减联合培哚普利叔丁胺片治疗气阴两虚夹瘀证早期糖尿病肾病临床观察[J].中国实验方剂学杂志,2023,29(1):105-112.
PANG J L,ZHONG R F.Clinical observation on Zuogui Pill plus perindopril tert butylamine tablet in the treatment of early diabetes nephropathy with qi yin deficiency and blood stasis[J].Chin J Exp Tradit Med Formulae,2023,29(1):105-112.
[5] BOURNE C M,TAABAZUING C Y.Harnessing pyroptosis for cancer immunotherapy[J].Cells,2024,13(4):346.
[6] WANG L,XIE X,CHEN Q,et al.Puerarin reduces diabetic nephropathy-induced podocyte pyroptosis by modulating the SIRT1/NLRP3/caspase-1 pathway[J].Mol Cell Endocrinol,2025,595:112409.
[7] CAO Y,HU L,CHEN R,et al.Unfolded protein response-activated NLRP3 inflammasome contributes to pyroptotic and apoptotic podocyte injury in diabetic kidney disease via the CHOP-TXNIP axis[J].Cell Signal,2025,130:111702.
[8] 中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南(2021年版)[J].中华糖尿病杂志,2021,41(4):388-410.
Microvascular Complications Group,diabetes Credit Association,Chinese Medical Association.Chinese guidelines for the prevention and treatment of diabetes nephropathy(2021 Edition)[J].Chin J Diabetes Mellitus,2021,41(4):388-410.
[9] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:232-234.
ZHENG X Y.Guidelines for clinical research of traditional Chinese medicine new drugs(Trial)[M].Beijing:Chin Med Sci and Techno Press,2002:232-234.
[10] 国家中医药管理局. 中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:233-237.
National Administration of Traditional Chinese Medicine. Guiding principles for clinical research of New Traditional Chinese Medicine (Trial)[S].Beijing: China Medical Science and Technology Press,2002:233-237.
[11] 唐利,廖常彬,王强,等.糖尿病肾病(Ⅲ~Ⅳ期)气阴两虚血瘀证患者应用益气养阴通络汤治疗效果及作用机制[J].中药材,2022,45(10):2507-2511.
TANG L,LIAO C B,WANG Q,et al.The therapeutic effect and mechanism of Yiqi Yangyin Tongluo Decoction on patients with diabetes nephropathy(stage III-IV)of qi yin deficiency and blood stasis syndrome[J].J Chin Med Mater,2022,45(10):2507-2511.
[12] 潘晓,赵玉,杨银,等.糖尿病肾病气阴两虚夹瘀型用药规律研究[J].中国中西医结合肾病杂志,2023,24(10):901-904.
PAN X,ZHAO Y,YANG Y,et al.Study on drug use rule of qi yin deficiency and blood stasis type in diabetes nephropathy[J].Chin J Integ Trad West Nep,2023,24(10):901-904.
[13] 谭曦,吴吉龙,刘婷,等.我国糖尿病肾病气阴两虚兼血瘀证研究的可视化分析[J].中国医药导报,2024,21(23):14-21.
TAN X,WU J L,LIU T,et al.Visual analysis of the research on qi yin deficiency and blood stasis syndrome of diabetes nephropathy in China[J].China Med Her,2024,21(23):14-21.
[14] 崔方强,孟元,王悦芬,等.保肾通络方对糖尿病肾脏病气阴两虚兼血瘀证的临床疗效观察[J].世界科学技术-中医药现代化,2024,26(7):1840-1846.
CUI F Q,MENG Y,WANG Y F,et al.Clinical observation on the therapeutic effect of Baoshen Tongluo Recipe on diabetes kidney disease with qi yin deficiency and blood stasis syndrome[J].World Sci Tech Moder Trad Chin Med,2024,26(7):1840-1846.
[15] 刘五梅,刘永飞,彭林,等.紫丹酸B对糖尿病肾病模型小鼠糖代谢和肾功能的改善作用及机制[J].中国药房,2023,34(23):2855-2860.
LIU W M,LIU Y F,PENG L,et al.Ameliorative effect and mechanism of Zidan acid B on glucose metabolism and renal function in mice with diabetes nephropathy[J].China Phar,2023,34(23):2855-2860.
[16] 谢丽倩,张莉,周建英,等.黄葵胶囊联合达格列净治疗对早期老年糖尿病肾病患者血糖水平,肾脏功能的影响[J].中国老年学杂志,2024,44(18):4431-4434.
XIE L Q,ZHANG L,ZHOU J Y,et al.The effect of Huangkui capsule combined with daggligin on blood sugar level and renal function in early elderly patients with diabetes nephropathy[J].Chin J Gerontol,2024,44(18):4431-4434.
[17] ZHANG S,GUO S,WANG P,et al.Dapagliflozin attenuates skeletal muscle atrophy in diabetic nephropathy mice through suppressing Gasdermin D-mediated pyroptosis[J].Int Immunopharmacol,2025,148:114088.
[18] WANG Y,YANG J,CHANG X,et al.Isoliquiritigenin alleviates diabetic kidney disease via oxidative stress and the TLR4/NF-κB/NLRP3 inflammasome pathway[J].Mol Nutr Food Res,2024,68(16):e2400215.
[19] 张皓,倪敏,张慧,等.糖尿病肾病患者外周血NOD样受体蛋白3炎症小体变化及其临床意义[J].中华内分泌外科杂志,2022,16(4):479-484.
ZHANG H,NI M,ZHANG H,et al.Changes of inflammatory corpuscles of NOD-like receptor protein 3 in peripheral blood of patients with diabetes nephropathy and its clinical significance[J].Chin J Endocr Surg,2022,16(4):479-484.
[20] 宋纯东,宋丹,贾评评,等.雷公藤多苷通过NLRP3/caspase-1/GSDMD细胞焦亡通路对糖尿病肾病大鼠肾损伤的影响[J].中国中药杂志,2023,48(10):2639-2645.
SONG C D,SONG D,JIA P P,et al.Effects of tripterygium wilfordii polyglycosides on renal injury in rats with diabetes nephropathy through NLRP3/caspase-1/GSDMD cell scorch pathway[J].China J Chin Mater Med,2023,48(10):2639-2645.
[21] 宋珂,宋纯东,段凤阳,等.益气养阴活血方调控Nrf2/NLRP3信号通路对糖尿病肾病大鼠的肾脏保护作用研究[J].中华中医药学刊,2024,42(2):117-121.
SONG K,SONG C D,DUAN F Y,et al.Study on the renal protective effect of Yiqi Yangyin Huoxue Recipe regulating Nrf2/NLRP3 signaling pathway on diabetes nephropathy rats[J].Chin Arch Tradit Chin Med,2024,42(2):117-121.